J
Jonathan Kimmelman
Researcher at McGill University
Publications - 183
Citations - 6253
Jonathan Kimmelman is an academic researcher from McGill University. The author has contributed to research in topics: Clinical trial & Research ethics. The author has an hindex of 33, co-authored 165 publications receiving 5310 citations. Previous affiliations of Jonathan Kimmelman include Ottawa Hospital Research Institute & Yale University.
Papers
More filters
Journal ArticleDOI
Sunburn and p53 in the onset of skin cancer
Annemarie Ziegler,Alan S. Jonason,David J. Leffellt,Jeffrey A. Simon,Jeffrey A. Simon,Harsh W. Sharma,Jonathan Kimmelman,Lee Remington,Tyler Jacks,Douglas E. Brash +9 more
TL;DR: Skin appears to possess a p53-dependent 'guardian-of-the-tissue' response to DNA damage which aborts precancerous cells, and if this response is reduced in a single cell by a prior p53 mutation, sunburn can select for clonal expansion of the p 53-mutated cell into the AK.
Journal ArticleDOI
Threats to validity in the design and conduct of preclinical efficacy studies: a systematic review of guidelines for in vivo animal experiments
Valerie C. Henderson,Jonathan Kimmelman,Dean Fergusson,Dean Fergusson,Jeremy M. Grimshaw,Jeremy M. Grimshaw,Daniel G. Hackam +6 more
TL;DR: A systematic review of preclinical research guidelines and organized recommendations according to the type of validity threat (internal, construct, or external) or programmatic research activity they primarily address provided a starting point for developing preclinical guidelines in other disease domains.
Journal ArticleDOI
Against pandemic research exceptionalism.
TL;DR: The urgency and scarcity of pandemics heighten the responsibility of key actors in the research enterprise to coordinate their activities to uphold the standards necessary to advance this mission, and the moral mission of research remains the same.
Journal ArticleDOI
Unsuccessful trial accrual and human subjects protections: An empirical analysis of recently closed trials:
TL;DR: The fraction and number of patients enrolled in trials that were at risk of not meaningfully addressing their primary research objective due to unsuccessful patient accrual are determined and Ethics bodies, investigators, and data monitoring committees should carefully scrutinize trial design, recruitment plans, and feasibility of achievingAccrual targets when designing and reviewing trials.
Journal ArticleDOI
Increasing placebo responses over time in U.S. clinical trials of neuropathic pain
Alexander H. Tuttle,Sarasa Tohyama,Tim Ramsay,Jonathan Kimmelman,Petra Schweinhardt,Gary J. Bennett,Jeffrey S. Mogil +6 more
TL;DR: It is found that placebo responses have increased considerably over this period, but drug responses have remained stable, leading to diminished treatment advantage, driven by studies conducted in the United States.